- Home
- CAN vs KMDA Comparison
CAN vs KMDA Comparison
Compare CAN & KMDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CAN
- KMDA
- Stock Information
- Founded
- CAN 2013
- KMDA 1990
- Country
- CAN Singapore
- KMDA Israel
- Employees
- CAN N/A
- KMDA N/A
- Industry
- CAN Semiconductors
- KMDA Biotechnology: Pharmaceutical Preparations
- Sector
- CAN Technology
- KMDA Health Care
- Exchange
- CAN Nasdaq
- KMDA Nasdaq
- Market Cap
- CAN 384.3M
- KMDA 399.7M
- IPO Year
- CAN 2019
- KMDA N/A
- Fundamental
- Price
- CAN $0.70
- KMDA $7.88
- Analyst Decision
- CAN Strong Buy
- KMDA Strong Buy
- Analyst Count
- CAN 6
- KMDA 3
- Target Price
- CAN $2.67
- KMDA $14.67
- AVG Volume (30 Days)
- CAN 28.9M
- KMDA 83.3K
- Earning Date
- CAN 08-14-2025
- KMDA 08-13-2025
- Dividend Yield
- CAN N/A
- KMDA 2.54%
- EPS Growth
- CAN N/A
- KMDA 31.21
- EPS
- CAN N/A
- KMDA 0.28
- Revenue
- CAN $317,009,000.00
- KMDA $167,235,000.00
- Revenue This Year
- CAN $160.28
- KMDA $14.51
- Revenue Next Year
- CAN $35.68
- KMDA $9.31
- P/E Ratio
- CAN N/A
- KMDA $27.89
- Revenue Growth
- CAN 65.68
- KMDA 11.83
- 52 Week Low
- CAN $0.53
- KMDA $5.08
- 52 Week High
- CAN $3.27
- KMDA $9.16
- Technical
- Relative Strength Index (RSI)
- CAN 53.84
- KMDA 69.92
- Support Level
- CAN $0.58
- KMDA $7.61
- Resistance Level
- CAN $0.62
- KMDA $7.86
- Average True Range (ATR)
- CAN 0.05
- KMDA 0.20
- MACD
- CAN 0.01
- KMDA 0.04
- Stochastic Oscillator
- CAN 75.53
- KMDA 77.46
About CAN Canaan Inc.
Canaan Inc is a developer of supercomputing chips and the manufacturer of digital blockchain computing equipment as well as the supplier of the overall scheme for computer software and hardware of digital blockchain. The revenues of the company are derived from the sales of Bitcoin mining machines and related parts.
About KMDA Kamada Ltd.
Kamada Ltd is a drug-focused, plasma-derived protein therapeutics company. It is involved in the business of developing, producing, and marketing specialty therapeutics using protein purification proprietary technology. Its product portfolio consists of Glassia, Bramitob, Foster, Ixiaro, Factor-IX, and others. The company has two segments namely, the Proprietary Products segment and the Distribution segment. It derives the majority of its revenue from the Proprietary products segment. The firm categorizes its products in Lung Disease, Vaccines, Haemophilia, Immunoglobulins, Critical care, and Diagnostics.